Shota:

• MiNA to receive $25M as up front and is eligible to receive $245M as milestones for each of five potential targets along with royalties on product sales resulting from the collaboration
• Lilly will be responsible for the pre/ clinical development of candidates and will retain exclusive commercialization rights for any products emerges during the collaboration. The new technology will expand the breadth of Lilly's RNA therapeutics platform
• The collaboration will deploy MiNA's small activating RNA technology platform to research up to five targets selected by Lilly addressing its key therapeutic areas

  Ref: PRNewswire | Image: Eli Lilly